![Dr. Rakesh Gaur MD, MPH, FACP, Hematologist (Blood Specialist)](/doctor_images/e/ee/2700954.jpg?v=f89b)
Dr. Rakesh Gaur MD, MPH, FACP
Hematologist-Oncologist | Hematology & Oncology
4321 Washington St Suite 4000 Kansas City MO, 64111About
Dr. Rakesh Gaur is a hematologist oncologist practicing in Kansas City, MO. Dr. Gaur specializes in the diagnosis, treatment and prevention of blood diseases such as anemia, hemophilia, sickle-cell disease, leukemia and lymphoma. Hematologist Oncologists are also trained in the study of cancer and its attack on other organs.
Education and Training
M.S. Ramaiah Medical College, Bangalore University MD
Maulana Azad Medical
University College of Medical Sciences and Guru Teg Bahadur Hospital 1990
M.S. Ramaiah Medical College 1989
Board Certification
Internal MedicineAmerican Board of Internal MedicineABIM
Provider Details
Clinical Trials
- Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer
- Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
- Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
- Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
- Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- Breast Cancer WEight Loss Study (BWEL Study)
- S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
- Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
- Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
- S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
- Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
- Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
- Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
- Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
- S0820, Adenoma and Second Primary Prevention Trial
- Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
- Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
- S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
- Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Cabozantinib S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
- Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
- Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
- Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
- Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Treatments
- Prostate Cancer
- Anemia
- Breast Cancer
- Lung Cancer
- Colon Cancer
- Acute Myeloid Leukemia (aml)
- Lymphoma
- Multiple Myeloma
- Leukemia
- Oral Surgery Procedures
- Extra Corporeal Shockwave Therapy
Professional Memberships
- Member Saint Luke's Care
Fellowships
- Hematology/Oncology, Madigan Army Medical Center, Madigan Hospital, WA 1998
- Med/Bone Marrow, Fred Hutchinson Cancer Research Center, Seattle, WA 1998
Dr. Rakesh Gaur MD, MPH, FACP's Practice location
Practice At 4321 Washington St Suite 4000
4321 Washington St Suite 4000 -Kansas City, MO 64111Get Direction
Dr. Rakesh Gaur MD, MPH, FACP's reviews
Write ReviewPatient Experience with Dr. Gaur
Recommended Articles
- Is Lymphoma-related PTSD Possible?
PTSD is something that one may not think of right away when thinking of chronic or life-threatening illnesses, but it should not be overlooked. Post-traumatic stress disorder, or PTSD, can affect all aspects of a person’s life and requires treatment by a specialist.The Diagnostic and Statistical...
- The Leukemia & Lymphoma Society to Expand Mission Against Blood Cancer
On July 19, 2017, the Leukemia & Lymphoma Society, or LLS, proclaimed that they would be expanding their initiative to beat acute myeloid leukemia. Referred to as "Beat AML Master Trial", the project aims to test new and innovative treatments for those suffering from AML. For more information...
- New Diagnostic Tool Approved for Lymphoma
A new diagnostic tool has been approved by the U.S. Food and Drug Administration (FDA) to help researchers identify leukemia and lymphoma cells by using a technique known as flow cytometry. A flow cytometry test for non-Hodgkin’s lymphoma (NHL) can help determine whether normal or abnormal DNA is...
- Touchdown For Lymphoma: Two Teams Put Rivalry Aside For a Cause
Everyone knows that some rivalries can get pretty heated - especially when sports are involved. However, two football teams recognize that there is something more important - supporting a girl with Hodgkin's lymphoma. Although she was a cheerleader for the football team, they are now turning the...
- Little Boy Tugs at Heartstrings of Entire Community: Be the Match!
Danny Feltwell, a young six-year-old boy, was diagnosed with T-cell lymphoblastic lymphoma when he was just two years old. After undergoing countless procedures and just four months from being considered fully cured, Danny relapsed and had to be re-hospitalized. The doctors found that a large tumor...
- Stem Cell Therapy Puts 4-year-old's Ultra Rare Lymphoma in Remission
4-year-old Jovon Moss was diagnosed with X-linked Lymphoproliferative Syndrome, a rare disorder of the immune system that led him to being taken back and forth to the hospital since his 3rd birthday.Jovon’s journey began in September of last year, when his mother, Brittany Fluellen, first began to...
Nearby Providers
- Dr. Joseph Patrick Mcguirk D.O.4320 Wornall Rd Kansas City MO 64111
- Dr. Addison Racoma Tolentino M.D.4321 WASHINGTON ST STE 4000 KANSAS CITY MO 64111
- Dr. Stephanie Lynn Graff M.D.4320 Wornall Rd Kansas City MO 64111
- Dr. Tracy Jill Miles D.O.4321 Washingtpn Kansas City MO 64111
- Dr. Navanshu Arora MD4321 Washington St Kansas City MO 64111
- Dr. Sunil Abhyankar M.D.4320 Wornall Rd Kansas City MO 64111
Nearest Hospitals
ST LUKES HOSPITAL OF KANSAS CITYl
4401 WORNALL ROAD KANSAS CITY MO 64111CHILDRENS MERCY HOSPITALl
2401 GILLHAM ROAD KANSAS CITY MO 64108